NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

Rhea-AI Summary

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) provided a Q3 update, highlighting advancements in its Phase IIb study for PrimeC, a drug designed for ALS. The company achieved enrollment milestones with over one-third of patients enrolled and aims for completion by late 2022. They also established collaborations to enhance ALS diagnostics and presented significant findings at key scientific conferences. With over $9 million in cash, NeuroSense is positioned to continue its clinical development. CEO Alon Ben-Noon acknowledged ALS community advancements and expressed gratitude to stakeholders.

Positive

• Phase IIb trial for PrimeC achieved over one-third patient enrollment.
• Strategic collaborations with NeuraLight and EverythingALS to enhance ALS diagnostics.
• Significant findings presented at major scientific forums.
• Over $9 million in cash available for continued development.

Negative

• None.

View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK

CAMBRIDGE, Mass., Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and CEO Alon Ben-Noon's remarks at the Nasdaq Opening Bell Ceremony on October 13, 2022. View the video here: LINK.

CEO's Q3 Update

As Q3 comes to a close, we would like to share the progress we've made at NeuroSense with PrimeC, our novel combination drug for ALS which is now in a Phase IIb study.

First, on behalf of everyone at NeuroSense, I want to congratulate Amylyx (Nasdaq: AMLX) and the entire ALS community on the FDA approval of RELYVRIO, a combination drug based on Phase II results.

We believe the powerful alliance of ALS researchers, drug developers, and patient advocacy groups will continue to advance more effective treatments to improve and extend quality of life for people living with ALS.

Towards this goal, our PrimeC ALS clinical development program achieved several milestones during Q3. Our Phase IIb trial, PARADIGM, enrolled over one-third of the patients necessary to complete the trial. We expect to open sites in Europe and the U.S. in the next few weeks, with the aim to complete enrollment towards the end of 2022. 

In Q3, we also completed enrollment and dosing of all subjects in a multi-dose PK study. We believe the results suggest that the PK profile of PrimeC supports the formulation's extended-release properties as the active components are released simultaneously.

During the quarter we entered two strategic collaborations, one with NeuraLight to advance the science of oculometric digital biomarkers in the detection and monitoring of ALS and another with EverythingALS Open Innovation Consortium, through which NeuroSense can further serve the ALS community and support the development of novel ALS measurement tools and diagnostics. I was honored to present at EverythingALS's Expert Talk Series in August.

NeuroSense participated in and presented at several key scientific conferences during Q3. At the World Orphan Drug Congress in Boston, we presented PrimeC's significant effect on ALS biomarkers. At the TRICALS Consortium 2022 Masterclass, the largest European research initiative to find a cure for ALS, we presented on the use of biomarkers in ALS trials.

I am also pleased to announce the publication of an article authored by our scientific team, along with leading ALS researchers, in the peer-reviewed journal: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. The article presented results from NeuroSense's Phase IIa study.

With over $9 million in cash and equivalents on our balance sheet at the end of Q3, we remain well positioned to complete our Phase IIb study and report topline results in mid-2023. I want to thank our dedicated team, our shareholders, and the ALS community.

I wish all of you good health and prosperity, 
Alon Ben-Noon 
NeuroSense Founder & CEO

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding timing of complete enrollment of our Phase IIb trial, PARADIGM and the timing of completion of such trial, patent applications; the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Such risks and uncertainties include the risk that there will be a delay in the enrollment and/or completion of our Phase IIb trial, PARADIGM and the risks set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 14, 2022. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

Video - https://www.youtube.com/watch?v=XaZQ4Z3cOFo
Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-therapeutics-provides-ceos-q3-update-and-nasdaq-opening-bell-ceremony-remarks-video-301652082.html

SOURCE NeuroSense

FAQ

What is NeuroSense Therapeutics' focus?

NeuroSense Therapeutics is focused on developing treatments for severe neurodegenerative diseases, primarily ALS.

What progress did NeuroSense report for Q3 2022?

NeuroSense reported key milestones in their Phase IIb trial for PrimeC, including substantial patient enrollment.

How much cash does NeuroSense have as of Q3 2022?

NeuroSense has over $9 million in cash and equivalents as of Q3 2022.

When are topline results for PrimeC expected?

Topline results for PrimeC are expected to be reported in mid-2023.

What collaborations did NeuroSense enter during Q3 2022?

NeuroSense entered collaborations with NeuraLight and EverythingALS to advance ALS diagnostics.